Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology

The Treatment Journey: Phases of Care and Protecting the Brain

At a Glance

Acute Lymphoblastic Leukemia (ALL) treatment is a multi-year process divided into three main phases: intensive induction to achieve remission, consolidation to clear residual cells, and a two to three year maintenance phase. It also includes spinal treatments to protect the brain from relapse.

Treating Acute Lymphoblastic Leukemia (ALL) is often described as a marathon, not a sprint. Because leukemia cells can hide in different parts of the body, treatment is divided into specific phases over a period of two to three years [1][2]. Each phase has a different goal and a different intensity level.

Phase 1: Induction (The “Reset”)

The first goal is to get you into complete remission, which means no leukemia cells are visible under a microscope [1][3].

  • The Goal: To quickly kill the majority of leukemia cells and allow your bone marrow to start making healthy blood cells again [3][4].
  • The Experience: This is the most intensive phase, usually lasting about four weeks. It typically requires a hospital stay because the chemotherapy will temporarily wipe out your immune system (a state called neutropenia) [5]. You will likely need blood and platelet transfusions during this time [6].
  • The Milestone: Early in this phase, you will likely have a central line (like a PICC line or a Port-a-cath) placed. This is a small tube that stays in your vein so you don’t need a needle stick every time you get medicine or have blood drawn [7][8].

CRITICAL SAFETY WARNING: Because your immune system is compromised, developing a fever during treatment is a medical emergency known as neutropenic fever. If you experience a fever, you must seek immediate emergency medical care, as infections can escalate rapidly [9].

Phase 2: Consolidation (The “Deep Clean”)

Once you are in remission, the next phase begins. Even if we can’t see the leukemia, some “hidden” Minimal Residual Disease (MRD) cells likely remain [1][4].

  • The Goal: To eradicate any leftover MRD [10].
  • The Experience: This phase can last several months and may involve different combinations of drugs to keep the cancer from becoming resistant [1][4]. You may be able to do some of this as an outpatient [11].

Phase 3: Maintenance (The “Insurance Policy”)

This is the longest part of the journey, typically lasting two to three years [12][2].

  • The Goal: To keep the leukemia from ever coming back [12][13].
  • The Experience: During this phase, treatment is much less intensive. You will mostly take daily and weekly oral medications (pills) at home, like 6-mercaptopurine (6-MP) and methotrexate [14][15]. You can often return to work or school during this time, though you will still have regular check-ups [12].

Protecting the Brain: CNS Prophylaxis

The brain and spinal cord are “sanctuary sites” for leukemia. Many chemotherapy drugs can’t cross the “blood-brain barrier,” so leukemia cells can hide there even when the rest of the body is clean [16][17].

  • Intrathecal Chemotherapy: To prevent a relapse in the brain, doctors must deliver medicine directly into the spinal fluid [18][19].
  • How it Works: This is done through a lumbar puncture (spinal tap) [18]. It may sound scary, but it is a standard part of the ALL protocol, and doctors often use local anesthesia or mild sedation to ensure you are comfortable [17]. This is done periodically throughout all phases of treatment [1].

The Importance of Adherence

During the long maintenance phase, it is vital to take every dose of your medication exactly as prescribed. Missing doses or taking the wrong amount can significantly increase the risk of the leukemia returning [20][21]. Your doctor will use genetic tests (like TPMT) to find the “just right” dose for your specific body [22][14].

Common questions in this guide

What happens during the induction phase of ALL treatment?
The induction phase is the first step of treatment and typically involves an intensive, four-week hospital stay. The goal is to quickly destroy the majority of leukemia cells and achieve complete remission so your bone marrow can start making healthy blood cells again.
Why do I need spinal taps if leukemia is a blood cancer?
Leukemia cells can hide in the brain and spinal cord because many chemotherapy drugs cannot cross the blood-brain barrier. To prevent a relapse in these areas, doctors deliver chemotherapy directly into the spinal fluid using a lumbar puncture, also known as a spinal tap.
How long does the maintenance phase last?
The maintenance phase is the longest part of treatment, typically lasting two to three years. During this time, you will take daily and weekly oral medications at home to keep the leukemia from returning, and many patients are able to return to work or school.
What is a neutropenic fever and why is it an emergency?
Neutropenic fever occurs when your immune system is severely weakened by chemotherapy and you develop a fever. This is a life-threatening medical emergency because your body cannot fight off infections, and you must seek immediate medical care.
Why is it so important to take my maintenance medications exactly as prescribed?
During the long maintenance phase, missing doses or taking the incorrect amount of your prescribed medication significantly increases the risk of the leukemia returning. Your doctor will use genetic testing to find the exact medication dose your body needs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific treatment protocol (e.g., COG or a pediatric-inspired adult regimen) will I be following?
  2. 2.Will I (or my child) need to stay in the hospital for the entire month of induction, or is any of it outpatient?
  3. 3.How many total intrathecal treatments (spinal taps) are planned, and what sedation options are available?
  4. 4.Have we done the genetic testing (TPMT and NUDT15) needed to set the correct dose for the maintenance phase?
  5. 5.What kind of central line is best for my situation—a PICC line or a Port-a-cath?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Acute Lymphoblastic Leukemia in Children.

    Hunger SP, Mullighan CG

    The New England journal of medicine 2015; (373(16)):1541-52 doi:10.1056/NEJMra1400972.

    PMID: 26465987
  2. 2

    Go with the Flow-Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009.

    Pawinska-Wasikowska K, Bukowska-Strakova K, Surman M, et al.

    Cancers 2022; (14(21)) doi:10.3390/cancers14215359.

    PMID: 36358778
  3. 3

    Altered brain function in new onset childhood acute lymphoblastic leukemia before chemotherapy: A resting-state fMRI study.

    Hu Z, Zou D, Mai H, et al.

    Brain & development 2017; (39(9)):743-750 doi:10.1016/j.braindev.2017.04.014.

    PMID: 28545980
  4. 4

    Acute lymphoblastic leukaemia.

    Malard F, Mohty M

    Lancet (London, England) 2020; (395(10230)):1146-1162 doi:10.1016/S0140-6736(19)33018-1.

    PMID: 32247396
  5. 5

    Hospital acquired pneumonia risk factors in children with Acute Lymphoblastic Leukemia on chemotherapy.

    Mairuhu AM, Andarsini MR, Setyoningrum RA, et al.

    Heliyon 2021; (7(6)):e07209 doi:10.1016/j.heliyon.2021.e07209.

    PMID: 34169164
  6. 6

    CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

    Angelova E, Audette C, Kovtun Y, et al.

    Haematologica 2019; (104(4)):749-755 doi:10.3324/haematol.2018.205252.

    PMID: 30361418
  7. 7

    Why do subcutaneous ports get stuck? A case-control study.

    Crook JL, Lu Z, Wang X, et al.

    Journal of pediatric surgery 2022; (57(9)):229-233 doi:10.1016/j.jpedsurg.2021.08.003.

    PMID: 34456040
  8. 8

    Complications during central venous access device removal in children: A systematic review and meta-analysis.

    Sakthivel M, Sakthivel D, Nataraja RM, Pacilli M

    Journal of pediatric surgery 2025; 162445 doi:10.1016/j.jpedsurg.2025.162445.

    PMID: 40623623
  9. 9

    Bacteriological Spectrum and Antibiotic Susceptibility on Blood Culture in Newly Diagnosed Pediatric Patients With Acute Lymphoblastic Leukemia During the Induction Phase.

    Fawad U

    Cureus 2022; (14(5)):e25470 doi:10.7759/cureus.25470.

    PMID: 35800825
  10. 10

    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).

    Fuster JL, Molinos-Quintana A, Fuentes C, et al.

    British journal of haematology 2020; (190(5)):764-771 doi:10.1111/bjh.16647.

    PMID: 32314348
  11. 11

    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

    Siegel SE, Advani A, Seibel N, et al.

    American journal of hematology 2018; (93(10)):1254-1266 doi:10.1002/ajh.25229.

    PMID: 30058716
  12. 12

    Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL).

    Stuckert AJ, Schafer ES, Bernhardt MB, et al.

    Leukemia & lymphoma 2020; (61(5)):1246-1249 doi:10.1080/10428194.2019.1702183.

    PMID: 31842647
  13. 13

    TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.

    Dreisig K, Brünner ED, Marquart HV, et al.

    Pediatric hematology and oncology 2021; (38(3)):227-238 doi:10.1080/08880018.2020.1842570.

    PMID: 33205673
  14. 14

    Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.

    Milosevic G, Kotur N, Krstovski N, et al.

    Journal of medical biochemistry 2018; (37(3)):320-327 doi:10.1515/jomb-2017-0060.

    PMID: 30598629
  15. 15

    Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia.

    Franca R, Stocco G, Kiren V, et al.

    Clinical pharmacology and therapeutics 2023; (114(5)):1082-1092 doi:10.1002/cpt.3022.

    PMID: 37550838
  16. 16

    Blastic Plasmacytoid Dendritic Cell Neoplasm in Children.

    Li Y, Sun V, Sun W, Pawlowska A

    Hematology/oncology clinics of North America 2020; (34(3)):601-612 doi:10.1016/j.hoc.2020.01.008.

    PMID: 32336423
  17. 17

    Managing CNS disease in adults with acute lymphoblastic leukemia.

    Larson RA

    Leukemia & lymphoma 2018; (59(1)):3-13 doi:10.1080/10428194.2017.1326597.

    PMID: 28535095
  18. 18

    Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.

    Salzer WL, Burke MJ, Devidas M, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(23)):2628-2638 doi:10.1200/JCO.19.02892.

    PMID: 32496902
  19. 19

    Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.

    Yeh TC, Liang DC, Hou JY, et al.

    Cancer 2018; (124(23)):4538-4547 doi:10.1002/cncr.31758.

    PMID: 30303520
  20. 20

    Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.

    Cohen G, Cooper S, Sison EA, et al.

    Pediatric blood & cancer 2020; (67(11)):e28360 doi:10.1002/pbc.28360.

    PMID: 32909665
  21. 21

    Utilization of Thiopurine Metabolites and Allopurinol in Pediatric Acute Lymphoblastic Leukemia: Consideration for an Algorithmic Approach.

    Mosher N, Torkildson J, Golden C, et al.

    Journal of pediatric hematology/oncology 2022; (44(2)):e521-e525 doi:10.1097/MPH.0000000000002313.

    PMID: 34486570
  22. 22

    Pharmacogenomics and ALL treatment: How to optimize therapy.

    Karol SE, Yang JJ

    Seminars in hematology 2020; (57(3)):130-136 doi:10.1053/j.seminhematol.2020.10.001.

    PMID: 33256902

This page provides educational information about the phases of Acute Lymphoblastic Leukemia treatment. It does not replace professional medical advice. Always consult your oncology team regarding your specific treatment protocol and schedule.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.